Profile data is unavailable for this security.
About the company
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
- Revenue in JPY (TTM)0.00
- Net income in JPY-3.44bn
- Incorporated2013
- Employees29.00
- LocationSanBio Co Ltd13F, St. Luke Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
- Phone+81 362643481
- Websitehttps://www.sanbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heartseed Inc | -100.00bn | -100.00bn | 45.49bn | 39.00 | -- | 6.32 | -- | -- | -- | -- | -- | 314.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.15 | -- | 0.00004 | -- | -- | -- | -- | -- | -- | -- |
| Healios KK | 104.00m | -2.22bn | 51.57bn | 65.00 | -- | 9.04 | -- | 495.87 | -25.70 | -25.70 | 0.9661 | 42.25 | 0.0067 | -- | 0.4952 | -- | -14.27 | -23.01 | -18.09 | -30.33 | -109.62 | -- | -2,143.27 | -2,221.73 | -- | -- | 0.5993 | -- | -81.43 | 30.96 | 47.65 | -- | -11.70 | -- |
| Shin Nippon Biomedical Laboratories Ltd | 31.37bn | 3.99bn | 69.90bn | 1.44k | 17.52 | 1.32 | 9.82 | 2.23 | 95.84 | 95.84 | 753.61 | 1,269.67 | 0.2983 | 1.01 | 5.59 | 21,848,400.00 | 3.73 | 9.90 | 5.31 | 14.82 | 51.59 | 52.68 | 12.50 | 23.35 | 0.6308 | -- | 0.4383 | 30.49 | 22.55 | 17.36 | -10.96 | 14.07 | 54.79 | 58.49 |
| 3-D Matrix Ltd | 8.47bn | 6.47m | 73.58bn | 114.00 | -- | 18.45 | 96.11 | 8.69 | -2.67 | -2.67 | 71.61 | 32.90 | 1.25 | 0.9849 | 4.61 | 74,276,300.00 | 0.0958 | -35.52 | 0.1222 | -46.12 | 68.67 | 59.66 | 0.0764 | -55.66 | 2.53 | -- | 0.2619 | -- | 51.11 | 59.47 | -878.94 | -- | -7.64 | -- |
| Takara Bio Inc | 44.15bn | -7.20bn | 114.52bn | 1.78k | -- | 1.13 | -- | 2.59 | -59.79 | -59.79 | 366.64 | 839.16 | 0.3535 | 1.48 | 5.49 | 24,816,750.00 | -5.73 | 8.66 | -6.12 | 9.70 | 53.99 | 63.76 | -16.20 | 17.16 | 3.83 | -4.82 | 0.0898 | 31.40 | 3.53 | 5.44 | -29.59 | -22.88 | 20.46 | 16.27 |
| GNI Group Ltd | 26.84bn | -4.41bn | 143.66bn | 867.00 | -- | 2.86 | -- | 5.35 | -80.69 | -80.69 | 511.58 | 900.92 | 0.3447 | 2.18 | 4.01 | -- | -9.40 | 0.5414 | -11.37 | 0.6475 | 74.49 | 80.97 | -27.26 | 1.28 | 3.79 | -2.99 | 0.0941 | -- | 13.67 | 22.39 | -501.65 | -- | 34.24 | -- |
| SanBio Co Ltd | 0.00 | -3.44bn | 176.04bn | 29.00 | -- | 330.15 | -- | -- | -48.26 | -48.26 | 0.00 | 6.83 | 0.00 | -- | -- | 0.00 | -138.65 | -47.32 | -177.12 | -57.01 | -- | -- | -- | -- | -- | -12.42 | 0.725 | -- | -- | -- | -9.02 | -- | -46.04 | -- |
| Peptidream Inc | 18.52bn | -3.75bn | 203.92bn | 621.00 | -- | 3.93 | -- | 11.01 | -28.99 | -28.99 | 143.24 | 398.78 | 0.2182 | 3.75 | 3.32 | -- | -4.42 | 8.02 | -5.86 | 9.72 | 40.61 | 64.82 | -20.24 | 18.77 | 1.53 | -16.77 | 0.2485 | 0.00 | -60.32 | 9.66 | -124.97 | -- | 24.52 | -- |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 06 Feb 2026 | 731.00k | 0.94% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 227.80k | 0.29% |
| Simplex Asset Management Co., Ltd.as of 05 Feb 2026 | 194.30k | 0.25% |
| BlackRock Advisors (UK) Ltd.as of 05 Feb 2026 | 129.30k | 0.17% |
| Geode Capital Management LLCas of 31 Dec 2025 | 48.10k | 0.06% |
| UBS Asset Management Switzerland AGas of 30 Jan 2026 | 42.80k | 0.06% |
| TIAA-CREF Investment Management LLCas of 31 Dec 2025 | 41.20k | 0.05% |
| Vanguard Asset Management Ltd.as of 31 Dec 2025 | 33.60k | 0.04% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 24.00k | 0.03% |
| Northern Trust Global Investments Ltd.as of 31 Jan 2026 | 21.20k | 0.03% |
